Dose-ranging study of SCH34117 in the treatment of patients with seasonal allergic rhinitis

Submission date	Recruitment status	Prospectively registered
02/08/2002	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
02/08/2002	Completed	[X] Results
Last Edited	Condition category	[] Individual participant data
06/09/2007	Respiratory	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

MD Heribert Staudinger

Contact details

Medical officer Schering-Plough Research Institute (SPRI) 2015 Galloping Hill Road, K-15-4 Kenilworth United States of America NJ 07033-0530

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

C98-001

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Seasonal allergic rhinitis

Interventions

Patients randomly assigned once-daily (QD) SCH34117 at doses of 2.5, 5, 7.5, 10, or 20 mg versus placebo for two weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

SCH34117

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/04/1998

Completion date

01/06/1998

Eligibility

Key inclusion criteria

Subjects 12 years or older with a two-year documented history of seasonal allergic rhinitis and otherwise in good health

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

1026

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/04/1998

Date of final enrolment

01/06/1998

Locations

Countries of recruitment

United States of America

Study participating centre Medical officer

Kenilworth United States of America NJ 07033-0530

Sponsor information

Organisation

Schering-Plough Research Institute (SPRI) (USA)

Sponsor details

2015 Galloping Hill Road, K-15-4 Kenilworth United States of America NJ 07033-0530

Sponsor type

Industry

Website

http://www.schering-plough.com/rd/rd02_research.html

ROR

https://ror.org/02891sr49

Funder(s)

Funder type

Industry

Funder Name

Schering-Plough Research Institute (SPRI) (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Results article Results 05/08/2002 Yes

No